Dr. Eric Biron, PhD, is a Regular Researcher at the CHU de Québec Research Center and Full Professor at the Faculty of Pharmacy of Laval University. Recognized for his contributions in peptide chemistry, combinatorial chemistry and antimicrobial peptides, Dr. Biron is particularly interested in the use of peptidomimetic macrocycles and heterocycles in medicinal chemistry. His research focuses on the discovery and development of novel therapeutic agents for the treatment of infectious diseases and cancers.

Discovery and development of new antibacterial agents

The alarming spread of antibiotic resistance has become a major problem in the treatment of bacterial infections. In this context, Dr. Biron is particularly interested in bacteriocins, a family of low molecular weight proteins produced by several bacteria, with strong antimicrobial activity. As they exhibit inhibitory activities against a large number of clinically important pathogenic bacteria, bacteriocins are increasingly considered as a promising substitute to antibiotics.

Based on their enormous potential in the pharmaceutical and medical areas, Dr. Biron’s laboratory is developing novel synthetic approaches to produce bacteriocins, and uses peptidomimetic strategies to optimize their pharmacological properties, improve their pharmacokinetic profile, and modify their spectrum of activity.

Development of new anti-cancer agents

Despite the progress made in various therapeutic approaches, the effectiveness of main anti-cancer therapies has reached a critical plateau in the treatment of several cancers. As a result, the demand for innovative and effective compounds with new modes of action is growing rapidly. In this context, Dr. Biron’s laboratory uses combinatorial chemistry to prepare libraries with high molecular diversity and perform target-based or phenotypic screenings to discover promising anti-cancer molecules.

In another approach, Dr. Biron is interested in the addiction of cancer cells to some multifunctional proteins that also play an important role in the resistance to treatment. In this case, Dr. Biron’s laboratory aims to develop functional inhibitors of these proteins through rational design, and peptidomimetic approaches.

CHUL
2705, boulevard Laurier
T-4-50
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

36 entries « 1 of 8 »

Bedard F, Hammami R, Zirah S, Rebuffat S, Fliss I, Biron E

Synthesis, antimicrobial activity and conformational analysis of the class IIa bacteriocin pediocin PA-1 and analogs thereof.

Journal Article

Sci Rep, 8 (1), pp. 9029, 2018, ISSN: 2045-2322.

Abstract | Links:

Bedard F, Biron E

Recent Progress in the Chemical Synthesis of Class II and S-Glycosylated Bacteriocins.

Journal Article

Front Microbiol, 9 , pp. 1048, 2018, ISSN: 1664-302X.

Abstract | Links:

Vézina-Dawod S, Gerber N, Liang X, Biron E

Convenient two-step synthesis of highly functionalized benzo-fused 1,4-diazepin-3-ones and 1,5-diazocin-4-ones by sequential Ugi and intramolecular SNAr reactions

Journal Article

Tetrahedron, 44 , pp. 6347-6355, 2017, ISSN: 0040-4020.

| Links:

Biron É, Vézina-Dawod S, Bédard F

Synthetic Strategies for Macrocyclic Peptides (Chapter 9)

Book Chapter

E, Marsault; ML, Peterson (Ed.): Practical medicinal chemistry with macrocycles : design, synthesis, and case studies, pp. 207-241, Hoboken, NJ, Wiley, 2017, ISBN: 9781119092568 (Print) / 9781119092582 (eBook).

| Links:

Jobin S, Mejean A, Galindo SM, Liang X, Vezina-Dawod S, Biron E

Toward solid-phase peptide fragment ligation by a traceless-Ugi multicomponent reaction approach.

Journal Article

Org Biomol Chem, 14 (47), pp. 11230-11237, 2016, ISSN: 1477-0520.

Abstract | Links:

36 entries « 1 of 8 »

Active projects

  • Centre de recherche en endocrinologie, métabolisme et inflammation, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Development and synthesis of molecular scaffolds for the manipulation of protein interactions and function, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2015-04-01 to 2020-03-31

Recently finished projects

  • Computational and machine learning approaches to improve design and screening of high bioactivity peptides for drug discovery, Subvention, Consortium québécois sur la découverte du médicament, Concours FOCUS, from 2014-12-01 to 2017-11-30
  • Developing a more efficient anti-cancer drug against breast cancer. (fonds 0493), Subvention, Fondation de l'Université Laval, from 2014-11-05 to 2017-04-04
  • Développement d'agents oxydants supportés sur polymères pour la préparation de peptides cycliques et composés macrocycliques, Partenariat, Conseil de recherches en sciences naturelles et génie Canada, Programme de subvention d'engagement partenarial (SEP), from 2016-05-01 to 2016-12-31
  • Les bactériocines: une alternative fort prometteuse aux antibiotiques dans les secteurs médical et vétérinaire?, Subvention, Fonds de recherche du Québec - Nature et technologies, Projet de recherche en équipe, from 2015-04-01 to 2018-03-31
Data provided by the Université Laval research projects registery